BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• 

  Policy

  BioNTech Hit with NIH Notice of Default Over COVID-19 Vaccine Royalties

  The National Institutes of Health claims BioNTech is in default regarding alleged royalty payments the agency contends it is owed in connection with the company’s COVID-19 vaccine Comirnaty.

  March 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Viking Touts Promising Phase I Data for Weight-Loss Pill Candidate

  The early-stage study showed that Viking Therapeutics’ oral obesity candidate VK2735, a dual agonist of the GLP-1 and GIP receptors, elicited a 3.3% reduction in mean body weight. The company plans to start a Phase II trial.

  March 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  FDA

  AstraZeneca’s Ultomiris Wins FDA Approval for Rare Autoimmune Disease

  AstraZeneca’s Alexion on Monday secured the fourth indication for Ultomiris, which can now be used to treat the rare autoimmune condition neuromyelitis optica spectrum disorder.

  March 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Delivery

  Brazil and Caring Cross to Produce Affordable CAR-T, Stem Cell Gene Therapies

  Brazil’s Ministry of Health and nonprofit Caring Cross announced a collaboration Tuesday aimed at local manufacturing of CAR-T cell and stem cell gene therapies at a much lower cost than Europe and the U.S.

  March 26, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  FDA

  6 Recently Approved Cell & Gene Therapies—And Why They Matter

  With several recent approvals in the space and more on the horizon, BioSpace looks at some of the key decisions and their larger significance both for patients and science.

  March 26, 2024

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Business

  C-Suite Shuffle: A2 Bio, Bayer, BioNTech and More

  See our latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.

  March 26, 2024

   · 

  4 min read

   · 

  Neil Versel
• 

  Drug Development

  Axsome Therapeutics’ Small Molecule Clears Phase III Trial in Narcolepsy

  Axsome clinched a late-stage victory for its chronic sleep disorder candidate AXS-12, which demonstrated significant improvement in cataplexy—the sudden loss of muscle tone while a person is awake—after five weeks.

  March 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Bayer’s Sweeping Executive Cuts, Wegovy’s Expanding Reach

  Bayer cut its C-suite nearly in half amid a massive restructuring. Meanwhile, the U.S. government says it will pay for Wegovy for patients with heart disease.

  March 26, 2024

   · 

  1 min read

   · 

  Greg Slabodkin, Heather McKenzie, Tyler Patchen
• 

  Policy

  Global Healthcare Celebrates Tech Successes & Grapples with Cybersecurity at HIMSS 2024

  Global healthcare and life sciences look toward automation, AI and Quantum to protect patient data and save lives.

  March 26, 2024

   · 

  7 min read

   · 

  Lori Ellis
• 

  Drug Development

  Opinion: Biopharma Should Prioritize Research on the Economics of Therapies

  Health economics and outcomes research (HEOR) is a critical but sometimes overlooked part of drug development. Decentralized trials now make it easy.

  March 26, 2024

   · 

  6 min read

   · 

  Joel Morse